The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema
NCT02718547 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2017-03-28
Summary
The Investigators propose to examine the effect of lowering the intraocular pressure on macular edema in Participants diagnosed with diabetic macular edema. Our theory is based on the assumption that lower intraocular pressure means higher Ocular Perfusion pressure, which may cause an improvement in retinal perfusion and thus an improvement in retinal oxygenation and reduced edema
Conditions
- Complications of Diabetes Mellitus
Interventions
- DRUG
-
Combigan
Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
Sponsors & Collaborators
-
Meir Hospital, Kfar Saba, Israel
collaborator OTHER -
Meir Medical Center
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-26
- Primary Completion
- 2018-03-30
- Completion
- 2018-07-31
Countries
- Israel
Study Locations
More Related Trials
-
Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
NCT05080803 ·Status: COMPLETED
-
Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.
NCT03458923 ·Status: UNKNOWN ·Phase: PHASE4
-
The Results of Pars Plana Vitrectomy in Diabetic Macular Edema
NCT03384901 ·Status: UNKNOWN
-
The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy
NCT02235935 ·Status: UNKNOWN
-
Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections
NCT01769599 ·Status: UNKNOWN
-
Treatment of Refractory Diabetic Macular Edema With Infliximab
NCT00505947 ·Status: TERMINATED ·Phase: PHASE3
-
Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
NCT01482871 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
NCT00367133 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
NCT00457470 ·Status: WITHDRAWN ·Phase: PHASE2
-
2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides
NCT00501878 ·Status: COMPLETED ·Phase: PHASE4
-
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
NCT07295704 ·Status: RECRUITING
-
Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME
NCT06314217 ·Status: COMPLETED ·Phase: NA
-
Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification
NCT07038967 ·Status: RECRUITING
-
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
NCT02949024 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema
NCT00464685 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
NCT01141881 ·Status: TERMINATED ·Phase: NA
-
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema
NCT00959725 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Imaging Parameters and DME Treatment Response
NCT02637245 ·Status: COMPLETED
-
Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection
NCT02933905 ·Status: COMPLETED
-
Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.
NCT05464953 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
NCT04288232 ·Status: COMPLETED ·Phase: PHASE3
-
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
NCT00789477 ·Status: COMPLETED ·Phase: PHASE2
-
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
NCT01331681 ·Status: COMPLETED ·Phase: PHASE3
-
Non-Responsive Diabetic Macular Edema and Spironolactone
NCT04853355 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effectiveness Of Suprachoroidal Injection In Diabetic Macular Edema
NCT06449768 ·Status: ACTIVE_NOT_RECRUITING